1 / 7

WG report backs: New TB Vaccines & TB/HIV

WG report backs: New TB Vaccines & TB/HIV. INAT Meeting November 12, 2010 Berlin. Goal and strategies for New TB Vaccines. Safe and effective in preventing TB - including M/XDR- in children, adolescents and adults, including people with HIV Types of Vaccines Preexposure

etta
Download Presentation

WG report backs: New TB Vaccines & TB/HIV

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. WG report backs:New TB Vaccines & TB/HIV INAT Meeting November 12, 2010 Berlin

  2. Goal and strategies forNew TB Vaccines • Safe and effective in preventing TB - including M/XDR- in children, adolescents and adults, including people with HIV • Types of Vaccines • Preexposure • Postexposure (Current BCG vaccine strategy) • Immunotherapy • Prime-Boost Strategy • Boost BCG or a recombinant BCG (rBCG) with a second, different vaccine designed to extend and enhance immune protection • Replace BCG with a recombinant BCG (rBCG) or attenuated live M.tb vaccine as the prime

  3. TB Vaccine Pipeline As of November 2009 Preclinical Phase I Phase II Phase IIb Phase III AERAS-422Aeras Mtb [∆lysA ∆panCD ∆secA2]Albert Einstein College of Medicine MTBVAC01 [∆phoP, ∆fad D26]University of Zaragoza, Institute Pasteur, TuBerculosis Vaccine Initiative (TBVI) HBHAInstitute Pasteur of Lille, INSERM, TBVI Hybrid 56Statens Serum Institute (SSI), Aeras, Intercell, TBVI HG85 A/BShanghai H&G Biotech Hybrid-I+IC31SSI, TBVI, Intercell M72GSK, Aeras MVA85A/AERAS-485Oxford-Emergent Tuberculosis Consortium (OETC), Aeras AERAS-402/ Crucell Ad35Crucell, Aeras M vaccae*Immodulon, NIH VPM 1002Max Planck, Vakzine Projekt Mgmt, TBVI rBCG30*UCLA, NIH, NIAID, Aeras AdAg85AMcMaster University Hybrid-I+CAF01SSI Hyvac 4/ AERAS-404SSI, Sanofi-Pasteur, Aeras, Intercell RUTIArchivel Farma M smegmatis* Prime Boost Post-infection Immunotherapy Preclinical vaccine candidates are not yet in clinical trials, but have been manufactured under Good Manufacturing Practice (GMP) for clinical use and have undergone some preclinical testing that meets regulatory standards. *indicates candidates that have been in clinical trials in the past, but are not currently being tested in clinical trials Source: Tuberculosis Vaccine Candidates – 2009; Stop TB Partnership Working Group on New TB Vaccines

  4. Facilitating access to New TB Vaccines Include new TB vaccines in EPI programs and extend the system to adolescent/adult vaccination Consider appropriate and innovative licensure procedures to accelerate access to market Strengthen health systems and identify innovative approaches to allow for mass vaccinations Find the “reasonable” balance between affordability, direct and indirect return on investment, societal benefits and sustainable production

  5. Role for INAT? • Can INAT play a role in clarifying the regulatory pathway? • Help to clarify WHO mechanism (eg. STAG’s role in SAGE) and accelerate pre-qualification (can this process be done in conjunction with phase III studies) • Assist in identifying what information is needed and by whom (eg. MOH, EPI and/or NTP) to make decisions about uptake of vaccines on country level

  6. Current priorities of TB/HIV WG • 3 I’s - IPT/ICF Guidelines • Global Consultation on the implementation considerations for scale-up of Xpert MTB/RIF • TB/HIV Collaborative Policy revision • Focus on delivery of decentralized HIV services (eg. ART) in TB settings • Ensuring linkages between diagnostic and care • Systematize and regulate use of GeneXpert at PEPFAR sites

  7. Role of INAT? • Influence NACP and HIV service providers • Need guidance from INAT on the role they can play for implementation WGs

More Related